Compare IRON & HTGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IRON | HTGC |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United States | United States |
| Employees | N/A | 50 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.9B |
| IPO Year | 2020 | N/A |
| Metric | IRON | HTGC |
|---|---|---|
| Price | $78.02 | $15.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $103.18 | $18.86 |
| AVG Volume (30 Days) | 492.5K | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 12.13% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $11.18 |
| Revenue Next Year | $283.52 | $5.24 |
| P/E Ratio | ★ N/A | $8.61 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.00 | $13.70 |
| 52 Week High | $99.50 | $19.67 |
| Indicator | IRON | HTGC |
|---|---|---|
| Relative Strength Index (RSI) | 48.40 | 53.99 |
| Support Level | $70.29 | $15.17 |
| Resistance Level | $82.65 | $16.39 |
| Average True Range (ATR) | 3.35 | 0.29 |
| MACD | -0.48 | -0.01 |
| Stochastic Oscillator | 25.06 | 54.12 |
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Hercules Capital Inc is a specialty finance company focused on providing senior secured loans to high-growth, venture capital-backed, and institutional-backed companies in a variety of technology and life sciences industries. The company's primary business objectives are to increase its net income, net investment income, and net asset value (NAV) through its investments mainly in structured debt or senior secured debt instruments of venture capital-backed and institutional-backed companies across a variety of technology-related industries at attractive yields. It finances companies belonging to computer software and hardware, networking systems, semiconductors, medical devices, bio-pharmaceutical, and other related sectors.